Molecular diagnostics involves the analysis of genetic material (DNA or RNA) to detect specific pathogens, mutations, or genetic markers associated with diseases.
The global Point-of-care Molecular Diagnostic Solution market was valued at US$ 4200 million in 2023 and is anticipated to reach US$ 7964.5 million by 2030, witnessing a CAGR of 9.7% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Point-of-care Molecular Diagnostic Solution, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Point-of-care Molecular Diagnostic Solution.
Report Scope
The Point-of-care Molecular Diagnostic Solution market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Point-of-care Molecular Diagnostic Solution market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Point-of-care Molecular Diagnostic Solution companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott Laboratories
F. Hoffmann-La Roche AG
Becton, Dickinson and Company
BioMerieux
Bio-Rad Laboratories, Inc.
Cepheid, Inc.
Danaher Corporation
Johnson and Johnson
Bayer Healthcare
Segment by Type
Assays & kits
Instruments & Analyzers
Software & Services
Segment by Application
Physicians’ Offices
Hospitals & ICUs
Research Institutes
Other End Users
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Point-of-care Molecular Diagnostic Solution companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Point-of-care Molecular Diagnostic Solution Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Assays & kits
1.2.3 Instruments & Analyzers
1.2.4 Software & Services
1.3 Market by Application
1.3.1 Global Point-of-care Molecular Diagnostic Solution Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Physicians’ Offices
1.3.3 Hospitals & ICUs
1.3.4 Research Institutes
1.3.5 Other End Users
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Point-of-care Molecular Diagnostic Solution Market Perspective (2019-2030)
2.2 Point-of-care Molecular Diagnostic Solution Growth Trends by Region
2.2.1 Global Point-of-care Molecular Diagnostic Solution Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Point-of-care Molecular Diagnostic Solution Historic Market Size by Region (2019-2024)
2.2.3 Point-of-care Molecular Diagnostic Solution Forecasted Market Size by Region (2025-2030)
2.3 Point-of-care Molecular Diagnostic Solution Market Dynamics
2.3.1 Point-of-care Molecular Diagnostic Solution Industry Trends
2.3.2 Point-of-care Molecular Diagnostic Solution Market Drivers
2.3.3 Point-of-care Molecular Diagnostic Solution Market Challenges
2.3.4 Point-of-care Molecular Diagnostic Solution Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Point-of-care Molecular Diagnostic Solution Players by Revenue
3.1.1 Global Top Point-of-care Molecular Diagnostic Solution Players by Revenue (2019-2024)
3.1.2 Global Point-of-care Molecular Diagnostic Solution Revenue Market Share by Players (2019-2024)
3.2 Global Point-of-care Molecular Diagnostic Solution Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Point-of-care Molecular Diagnostic Solution Revenue
3.4 Global Point-of-care Molecular Diagnostic Solution Market Concentration Ratio
3.4.1 Global Point-of-care Molecular Diagnostic Solution Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Point-of-care Molecular Diagnostic Solution Revenue in 2023
3.5 Point-of-care Molecular Diagnostic Solution Key Players Head office and Area Served
3.6 Key Players Point-of-care Molecular Diagnostic Solution Product Solution and Service
3.7 Date of Enter into Point-of-care Molecular Diagnostic Solution Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Point-of-care Molecular Diagnostic Solution Breakdown Data by Type
4.1 Global Point-of-care Molecular Diagnostic Solution Historic Market Size by Type (2019-2024)
4.2 Global Point-of-care Molecular Diagnostic Solution Forecasted Market Size by Type (2025-2030)
5 Point-of-care Molecular Diagnostic Solution Breakdown Data by Application
5.1 Global Point-of-care Molecular Diagnostic Solution Historic Market Size by Application (2019-2024)
5.2 Global Point-of-care Molecular Diagnostic Solution Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Point-of-care Molecular Diagnostic Solution Market Size (2019-2030)
6.2 North America Point-of-care Molecular Diagnostic Solution Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Point-of-care Molecular Diagnostic Solution Market Size by Country (2019-2024)
6.4 North America Point-of-care Molecular Diagnostic Solution Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Point-of-care Molecular Diagnostic Solution Market Size (2019-2030)
7.2 Europe Point-of-care Molecular Diagnostic Solution Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Point-of-care Molecular Diagnostic Solution Market Size by Country (2019-2024)
7.4 Europe Point-of-care Molecular Diagnostic Solution Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Point-of-care Molecular Diagnostic Solution Market Size (2019-2030)
8.2 Asia-Pacific Point-of-care Molecular Diagnostic Solution Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Point-of-care Molecular Diagnostic Solution Market Size by Region (2019-2024)
8.4 Asia-Pacific Point-of-care Molecular Diagnostic Solution Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Point-of-care Molecular Diagnostic Solution Market Size (2019-2030)
9.2 Latin America Point-of-care Molecular Diagnostic Solution Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Point-of-care Molecular Diagnostic Solution Market Size by Country (2019-2024)
9.4 Latin America Point-of-care Molecular Diagnostic Solution Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Point-of-care Molecular Diagnostic Solution Market Size (2019-2030)
10.2 Middle East & Africa Point-of-care Molecular Diagnostic Solution Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Point-of-care Molecular Diagnostic Solution Market Size by Country (2019-2024)
10.4 Middle East & Africa Point-of-care Molecular Diagnostic Solution Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Point-of-care Molecular Diagnostic Solution Introduction
11.1.4 Abbott Laboratories Revenue in Point-of-care Molecular Diagnostic Solution Business (2019-2024)
11.1.5 Abbott Laboratories Recent Development
11.2 F. Hoffmann-La Roche AG
11.2.1 F. Hoffmann-La Roche AG Company Detail
11.2.2 F. Hoffmann-La Roche AG Business Overview
11.2.3 F. Hoffmann-La Roche AG Point-of-care Molecular Diagnostic Solution Introduction
11.2.4 F. Hoffmann-La Roche AG Revenue in Point-of-care Molecular Diagnostic Solution Business (2019-2024)
11.2.5 F. Hoffmann-La Roche AG Recent Development
11.3 Becton, Dickinson and Company
11.3.1 Becton, Dickinson and Company Company Detail
11.3.2 Becton, Dickinson and Company Business Overview
11.3.3 Becton, Dickinson and Company Point-of-care Molecular Diagnostic Solution Introduction
11.3.4 Becton, Dickinson and Company Revenue in Point-of-care Molecular Diagnostic Solution Business (2019-2024)
11.3.5 Becton, Dickinson and Company Recent Development
11.4 BioMerieux
11.4.1 BioMerieux Company Detail
11.4.2 BioMerieux Business Overview
11.4.3 BioMerieux Point-of-care Molecular Diagnostic Solution Introduction
11.4.4 BioMerieux Revenue in Point-of-care Molecular Diagnostic Solution Business (2019-2024)
11.4.5 BioMerieux Recent Development
11.5 Bio-Rad Laboratories, Inc.
11.5.1 Bio-Rad Laboratories, Inc. Company Detail
11.5.2 Bio-Rad Laboratories, Inc. Business Overview
11.5.3 Bio-Rad Laboratories, Inc. Point-of-care Molecular Diagnostic Solution Introduction
11.5.4 Bio-Rad Laboratories, Inc. Revenue in Point-of-care Molecular Diagnostic Solution Business (2019-2024)
11.5.5 Bio-Rad Laboratories, Inc. Recent Development
11.6 Cepheid, Inc.
11.6.1 Cepheid, Inc. Company Detail
11.6.2 Cepheid, Inc. Business Overview
11.6.3 Cepheid, Inc. Point-of-care Molecular Diagnostic Solution Introduction
11.6.4 Cepheid, Inc. Revenue in Point-of-care Molecular Diagnostic Solution Business (2019-2024)
11.6.5 Cepheid, Inc. Recent Development
11.7 Danaher Corporation
11.7.1 Danaher Corporation Company Detail
11.7.2 Danaher Corporation Business Overview
11.7.3 Danaher Corporation Point-of-care Molecular Diagnostic Solution Introduction
11.7.4 Danaher Corporation Revenue in Point-of-care Molecular Diagnostic Solution Business (2019-2024)
11.7.5 Danaher Corporation Recent Development
11.8 Johnson and Johnson
11.8.1 Johnson and Johnson Company Detail
11.8.2 Johnson and Johnson Business Overview
11.8.3 Johnson and Johnson Point-of-care Molecular Diagnostic Solution Introduction
11.8.4 Johnson and Johnson Revenue in Point-of-care Molecular Diagnostic Solution Business (2019-2024)
11.8.5 Johnson and Johnson Recent Development
11.9 Bayer Healthcare
11.9.1 Bayer Healthcare Company Detail
11.9.2 Bayer Healthcare Business Overview
11.9.3 Bayer Healthcare Point-of-care Molecular Diagnostic Solution Introduction
11.9.4 Bayer Healthcare Revenue in Point-of-care Molecular Diagnostic Solution Business (2019-2024)
11.9.5 Bayer Healthcare Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Abbott Laboratories
F. Hoffmann-La Roche AG
Becton, Dickinson and Company
BioMerieux
Bio-Rad Laboratories, Inc.
Cepheid, Inc.
Danaher Corporation
Johnson and Johnson
Bayer Healthcare
Ěý
Ěý
*If Applicable.
